Nephros, Inc.

As of November 7, 2025, Nephros, Inc. is considered a very attractive investment due to its undervaluation, highlighted by a favorable PEG ratio of 0.23 compared to its peer Nutriband, Inc., despite lacking return data for comparison.

As of November 7, 2025, Nephros, Inc. has improved its valuation grade to very attractive, showing strong metrics with a P/E ratio of 36 and a PEG ratio of 0.23, despite a recent 19.30% stock decline, while year-to-date returns of 212.93% significantly outperform the S&P 500's 14.40%.

As of October 24, 2025, Nephros, Inc. is considered attractive but overvalued, with a high P/E ratio of 36 compared to the peer average of 31.39, and despite decent returns, its low PEG ratio of 0.23 suggests insufficient growth to justify its valuation.

As of October 1, 2023, Nephros, Inc. is considered undervalued with a P/E ratio of 15.2 and a P/B ratio of 2.1, outperforming peers like Fresenius Medical Care and Baxter International, indicating an attractive investment opportunity.

As of November 1, 2023, there is insufficient technical data for Nephros, Inc. to determine a bullish or bearish outlook.

As of March 2022, the management team of Nephros, Inc. includes Andrew Astor as President and CEO, alongside Board members Thomas Gwydir, Alisa Lask, Malcom Persen, Oliver Spandow, and Independent Director Arthur Amron.

Nephros, Inc. is a micro-cap company that develops and sells water purification products for medical and commercial markets, with recent net sales of $5 million and a net profit of $1 million. It has a market cap of $40.07 million and key metrics include a P/E ratio of 36.00 and a return on equity of 8.62%.